Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumescent Antibiotic Delivery for SSI Prevention
NCT02503904Phase 3Unknown
- Start
- Oct 2015
- Primary completion
- Jun 2019
- Modality
- Reversible Covalent Inhibitors
01
Overview
Phase 3, randomised, open-label trial of cefazolin and metronidazole in surgical site infection (SSI) (2 arms). Primary endpoint: Surgical Site Infections at 30 days. Status: unknown.
02
Drugs
cefazolinmetronidazole
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT02503904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503904.